Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Child/Adolescent Anxiety Multimodal Treatment Study
NCT00052078Phase 3Completed
- Sponsor
- Johns Hopkins University
- Start
- Jan 2003
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sertraline in separation anxiety disorder (SAD), Social Anxiety Disorder (SAD) and generalized anxiety disorder (GAD) (4 arms), sponsored by Johns Hopkins University. Primary endpoint: Clinical Global Impression - Improvement Scale at 12 weeks. Started Jan 2003; status: completed.
02
Drugs
sertraline
03
Conditions
separation anxiety disorder (SAD)Social Anxiety Disorder (SAD)generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00052078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052078.